Parathyroid hormone (1-34) (human): Mechanistic Benchmarks for Calcium Homeostasis and Kidney/Bone Research

Executive Summary: Parathyroid hormone (1-34) (human) is a synthetic peptide fragment with the identical N-terminal 34-residue sequence as endogenous human PTH, enabling high-fidelity activation of PTH1R and PTH2R receptors (APExBIO, product page). The peptide displays an IC₅₀ of 0.22 nM for cAMP production in transfected HEK293 cells, ensuring robust signal transduction. It regulates bone and kidney calcium flux via direct modulation of bone resorption, renal reabsorption, and vitamin D synthesis (Redefining Translational Research, internal article). In vivo, subcutaneous dosing increases both trabecular and cortical bone mass in rat models. The product is highly soluble in DMSO and water, supplied at >97.8% purity, and intended strictly for scientific research.

Biological Rationale

Parathyroid hormone (1-34) (human), also referred to as PTH (1-34), is a biologically active peptide fragment derived from the full-length human parathyroid hormone. It consists of the first 34 amino acids (H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH) and has a molecular weight of 4117.72 Da (APExBIO product details). PTH (1-34) is secreted physiologically by the chief cells of the parathyroid glands. It is a principal regulator of serum calcium concentrations, acting through parathyroid hormone 1 receptor (PTH1R) and parathyroid hormone 2 receptor (PTH2R) expressed on bone, kidney, and other tissues (Huang et al., 2025).

This peptide fragment is used extensively as a research tool to dissect calcium homeostasis, bone metabolism, and kidney function, especially in disease models where precise control of PTH receptor signaling is required (Mechanistic Foundation article). Its short sequence retains full biological activity, enabling high receptor specificity and minimal off-target effects.

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) binds with high affinity to PTH1R and PTH2R, which are G protein-coupled receptors (GPCRs) expressed on osteoblasts, renal tubular cells, and other target tissues. Upon binding, the peptide activates two main intracellular signaling cascades:

• cAMP/PKA Pathway: PTH (1-34) stimulates adenylate cyclase, increasing cyclic AMP (cAMP) production. In transfected human HEK293 cells, the IC₅₀ for cAMP stimulation is 0.22 nM under standard buffer conditions (pH 7.4, 37°C) (APExBIO).
• Inositol Phosphate Synthesis: Activation of phospholipase C results in increased inositol triphosphate (IP3) production, mobilizing intracellular calcium stores.

At the tissue level, PTH (1-34) exerts the following effects:

• Bone: Promotes osteoclastic bone resorption and stimulates osteoblastic bone formation, leading to net calcium release into circulation.
• Kidney: Increases reabsorption of calcium and magnesium in the distal tubules and thick ascending limb; reduces phosphate reabsorption.
• Intestine: Indirectly enhances intestinal calcium absorption via increased production of activated vitamin D (1,25-dihydroxyvitamin D).

This dual action makes PTH (1-34) a valuable research tool for dissecting PTH/PTHrP receptor signaling and for modeling endocrine regulation in organoid and assembloid systems (Huang et al., 2025).

Evidence & Benchmarks

• PTH (1-34) (human) exhibits an IC₅₀ of 0.22 nM for cAMP stimulation in HEK293 cells expressing human PTH1R, indicating high potency (APExBIO, product page).
• Subcutaneous administration of 10 or 40 μg/kg/day in male Fisher 344 rats for up to 4 weeks results in dose- and time-dependent increases in trabecular and cortical bone mass (APExBIO, product page).
• Kidney assembloid models using PTH (1-34) allow for high-fidelity simulation of PTH-driven calcium flux and signaling, supporting translational disease modeling (Huang et al., 2025, DOI).
• The peptide is soluble at ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water, but insoluble in ethanol, enabling flexible integration into a variety of life science protocols (APExBIO).
• PTH (1-34) supports robust, reproducible signaling in advanced cell-based and organoid assays, as detailed in scenario-driven protocols (Optimizing Cell Assays article).

Applications, Limits & Misconceptions

PTH (1-34) (human) is primarily used as a research reagent in the following applications:

• Modeling calcium homeostasis in both in vitro and in vivo settings.
• Bone metabolism research, including osteoporosis and osteopenia models.
• Kidney physiology and disease modeling, especially in assembloid and organoid platforms.
• Dissection of PTH/PTHrP receptor signaling and downstream pathways.

This article extends the mechanistic scope described in Mechanistic Foundation by integrating new evidence from kidney assembloid systems (Huang et al., 2025) and providing actionable workflow guidance not present in prior reviews.

For researchers seeking practical, scenario-driven solutions for cell viability, proliferation, and kidney assembloid assays, see "Optimizing Cell Assays with Parathyroid hormone (1-34) (human)", which delivers stepwise protocols. This article updates that piece by outlining mechanistic benchmarks and highlighting translational context.

Common Pitfalls or Misconceptions

• Not for Diagnostic or Therapeutic Use: PTH (1-34) (human) (A1129) is strictly for laboratory research; it is not approved for clinical or diagnostic applications (APExBIO).
• Storage Stability: Solutions are not stable for long-term storage; freshly prepared aliquots are recommended to ensure activity.
• Solubility Limits: The peptide is insoluble in ethanol; use only DMSO or water at the recommended concentrations.
• Species Cross-reactivity: While active on human PTH1R/PTH2R, efficacy in non-mammalian models must be independently verified.
• Overlooked Pathway Complexity: Responses may differ between cell types and tissues due to context-dependent receptor expression and downstream effectors.

Workflow Integration & Parameters

For optimal results, dissolve PTH (1-34) (human) at ≥399.3 mg/mL in DMSO or ≥19.88 mg/mL in water, ensuring homogeneity by vortexing and brief sonication if necessary. Use immediately after reconstitution; aliquot and store at -20°C under desiccated conditions to preserve integrity (APExBIO). Avoid repeated freeze-thaw cycles. In cell-based assays, titrate concentrations to match the receptor expression and desired signaling output; typical working concentrations range from 0.1 nM to 100 nM, depending on endpoint sensitivity and receptor density (product page).

For kidney assembloid models, PTH (1-34) can be added directly to the culture medium, supporting robust, reproducible activation of PTH1R-dependent pathways (see Huang et al., 2025). For additional advice on integrating PTH (1-34) into complex organoid systems, refer to "Scenario-Driven Solutions", which contrasts standard and advanced workflow challenges.

Conclusion & Outlook

PTH (1-34) (human) is a validated, high-purity tool for dissecting PTH/PTHrP receptor biology in bone and kidney research. Its robust cAMP and inositol phosphate signaling, together with high solubility and stability, support reproducible results in both cell and organoid models. APExBIO's A1129 reagent is a gold standard for mechanistic and translational research. As kidney assembloid and organoid technologies advance, PTH (1-34) will remain central to high-fidelity disease modeling and therapeutic discovery (Huang et al., 2025).